变应原特异性舌下含服免疫治疗儿童螨过敏性哮喘的对照研究

Control study of sublingual immunotherapy to children with allergic asthma induced by mites

目的评估变应原特异性舌下含服免疫治疗(SLIT)儿童过敏性哮喘的临床疗效及安全性。方法将62例尘螨过敏的哮喘患儿随机分为两组,SLIT组(n=31)在抗哮喘药物治疗的同时,采用SLIT 3年;对照组(n=31)仅采用抗哮喘药物治疗。两组均随访3年,比较治疗前后的哮喘症状评分、用药评分、肺功能以及不良反应发生情况。结果 SLIT组患者的哮喘症状评分、用药评分、肺功能指标与对照组比较明显改善(均P<0.01)。SLIT组无严重不良事件发生。结论变应原特异性舌下含服免疫治疗螨诱导的儿童过敏性哮喘安全有效。

Objective To evaluate the safety and efficacy of sublingual immunotherapy （SLIT） to children with allergic asthma. Methods A total of 62 children with allergic asthma induced by mites were assigned two groups at random. Trial group （ n = 31 ） underwent 3-year SLIT in combination with anti-asthma drugs. Control group （ n = 31 ） received anti-asthma drugs alone. They were all followed up for 3 years. Asthma symptom score, drug score, pulmonary function and adverse effect were assessed during the study. Results The asthma symptom score, drug score and pulmonary function of the trial group all improved more significantly after treatment, compared with that of the control group （P 〈 0.01 ）. No severe adverse events occurred in the trial group. Conclusion SLIT is efficacious and safe to children with allergic asthma induced by mites.